<iframe src="//www.googletagmanager.com/ns.html?id=GTM-MX3DVL" height="0" width="0" style="display:none;visibility:hidden"></iframe>Pestalozzi advises The European Investment Bank on a EUR 20 million financing agreement with BioVersys | Pestalozzi Attorneys at Law

Pestalozzi advises The European Investment Bank on a EUR 20 million financing agreement with BioVersys

14.04.2021

On April 14, 2021, the European Investment Bank (EIB), the lending arm of the European Union, and BioVersys AG, a privately-owned clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, announced the signing of a EUR 20 million venture debt transaction. The financing supports the company’s research and development of a diverse pipeline of drugs that address antimicrobial resistance (AMR). AMR causes the majority of antimicrobial therapies to become obsolete. Due to its potential to trigger a new bacterial pandemic, AMR has been widely recognised as the top priority health threat by the WHO, G7 and G20.

Pestalozzi advised EIB on all Swiss law aspects of this transaction.

The Pestalozzi team included:
Franz Schubiger (Partner - Corporate / M&A, Life Sciences), Nils Harbeke (Partner - Tax), Urs Kloeti (Partner - Financial Services), Daniela Fritsch (Associate - Financial Services), Severin Etzensperger (Associate - IP & TMT, Life Sciences)

To the top

Cookies

Close
We use cookies in order to optimally design and continuously improve our website. By continuing to use the website you consent to the use of cookies. For further information about cookies please view our data protection statement.